Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global GMP Plasmid DNA Manufacturing market size was valued at USD 740.12 million in 2022 and is expected to expand at a CAGR of 11.97% during the forecast period, reaching USD 1458.52 million by 2028.
A circular double-stranded DNA present in the cytoplasm of a bacteria that replicate independently from the bacterial chromosome is called a plasmid DNA. The unique property of self-replication makes it unique and available to use in different molecular genetic research such as gene therapy, gene transfer and recombinant DNA technology. Good Manufacturing Practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. GMP Plasmid DNA Manufacturing meets the GMP standard.
Pharmaceutical companies cooperate with contract plasmid manufacturers to speed up the production of nucleic acid-based biopharmaceuticals-including Covid-19 vaccine and gene therapy-based drugs. Plasmids are essential for nucleic acid-based vaccines and gene therapy. Efficient plasmid production is an important factor for large-scale production of several Covid-19 vaccines.
Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, signed an agreement with INOVIO Pharmaceuticals Inc. to manufacture COVID-19 DNA vaccine candidate, INO-4800.
Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and Scancell Holdings plc (Scancell), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announced that they have entered into a collaboration for Cobra to manufacture Scancell COVID-19 vaccine. The epidemic has promoted the development of GMP Plasmid DNA Manufacturing industry.
Rapid growth of the biopharmaceutical industry
In the past two years, the number of research new drugs has increased greatly, and many drugs have been authorized for commercial sale. Due to this growth, contract manufacturers providing GMP-grade plasmids are trying to keep up with the increasing demand. The recent epidemic situation has aggravated this problem, because many candidate vaccines are being developed, including DNA-based vaccines and mRNA-based vaccines, in which plasmid DNA is needed as the starting material of mRNA transcription in vitro. The continuous growth of downstream demand will promote the development of GMP Plasmid DNA Manufacturing industry.
The manufacturing process of GMP Plasmid DNA Manufacturing is complicated
High-quality plasmid DNA is a key component in cell and gene therapy manufacturing, so it is in great demand. This leads to the need to optimize manufacturing to meet the volume and quality requirements in the manufacture of therapeutic drugs. Because of the large size, shear sensitivity, high viscosity of plasmid DNA (pDNA) and the similarity between pDNA and impurities in the manufacturing process, its manufacturing faces many challenges.
Region Overview:
In 2021, the share of the GMP Plasmid DNA Manufacturing market in North America stood at 45.6%.
Company Overview:
Aldevron is one of the major players operating in the GMP Plasmid DNA Manufacturing market, holding a share of 34.65% in 2021.
Aldevron
Aldevron has grown into a world-class service organization specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe.
Kaneka Eurogentec S.A.
Eurogentec, part of Kaneka Corporation, is an international biotechnology supplier, based in Belgium, who specializes in genomics and proteomics. The company is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market.
Segmentation Overview:
As for product types, the Clinical Therapeutics segment held the largest market share in 2021.
Pre-Clinical Therapeutics
Pre-clinical is the stage that begins before clinical practice, during which important feasibility, repeated testing and drug safety data are usually collected in experiments.
Clinical Therapeutics
Clinical refers to direct contact with patients and actual observation of patients.
Marketed Therapeutics
Marketed means product to market stage.
Application Overview:
The market's largest segment by application is the segment Gene Therapy, with a market share of 36.02% in 2021.
Gene Therapy
Gene Therapy focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material.
DNA Vaccines
DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response.
Immunotherapy
Immunotherapy is the treatment of disease by activating or suppressing the immune system.
This report elaborates on the market size, market characteristics, and market growth of the GMP Plasmid DNA Manufacturing industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of GMP Plasmid DNA Manufacturing. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global GMP Plasmid DNA Manufacturing Market Report Include:
Market Size Estimates: GMP Plasmid DNA Manufacturing market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: GMP Plasmid DNA Manufacturing market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the GMP Plasmid DNA Manufacturing market
Segment Market Analysis: GMP Plasmid DNA Manufacturing market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: GMP Plasmid DNA Manufacturing market situations and prospects in major and top regions and countries
GMP Plasmid DNA Manufacturing Market
GMP Plasmid DNA Manufacturing Industry Chain: GMP Plasmid DNA Manufacturing market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
GMP Plasmid DNA Manufacturing Industry News, Policies by regions
GMP Plasmid DNA Manufacturing Industry Porters Five Forces Analysis
Key players in the global GMP Plasmid DNA Manufacturing market are covered in Chapter 2:
VGXI, Inc
Esco Aster
Biovian
LakePharma
Charles River
VectorBuilder
Thermo Fisher Scientific
GenScript ProBio
Nature Technology Corporation
Catalent Biologics
BioXcellence
PlasmidFactory
Creative Biolabs
WuXi Advanced Therapies
Waisman Biomanufacturing
Kaneka Eurogentec S.A.
Aldevron
In Chapter 6 and Chapter 9, on the basis of types, the GMP Plasmid DNA Manufacturing market from 2018 to 2028 is primarily split into:
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
In Chapter 7 and Chapter 10, on the basis of applications, the GMP Plasmid DNA Manufacturing market from 2018 to 2028 covers:
Gene Therapy
DNA Vaccines
Immunotherapy
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global GMP Plasmid DNA Manufacturing market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the GMP Plasmid DNA Manufacturing industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of GMP Plasmid DNA Manufacturing market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the GMP Plasmid DNA Manufacturing industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on GMP Plasmid DNA Manufacturing market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the GMP Plasmid DNA Manufacturing market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed GMP Plasmid DNA Manufacturing market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
A circular double-stranded DNA present in the cytoplasm of a bacteria that replicate independently from the bacterial chromosome is called a plasmid DNA. The unique property of self-replication makes it unique and available to use in different molecular genetic research such as gene therapy, gene transfer and recombinant DNA technology. Good Manufacturing Practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. GMP Plasmid DNA Manufacturing meets the GMP standard.
Pharmaceutical companies cooperate with contract plasmid manufacturers to speed up the production of nucleic acid-based biopharmaceuticals-including Covid-19 vaccine and gene therapy-based drugs. Plasmids are essential for nucleic acid-based vaccines and gene therapy. Efficient plasmid production is an important factor for large-scale production of several Covid-19 vaccines.
Kaneka Eurogentec S.A., an affiliate of Kaneka Corporation, signed an agreement with INOVIO Pharmaceuticals Inc. to manufacture COVID-19 DNA vaccine candidate, INO-4800.
Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and Scancell Holdings plc (Scancell), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announced that they have entered into a collaboration for Cobra to manufacture Scancell COVID-19 vaccine. The epidemic has promoted the development of GMP Plasmid DNA Manufacturing industry.
Rapid growth of the biopharmaceutical industry
In the past two years, the number of research new drugs has increased greatly, and many drugs have been authorized for commercial sale. Due to this growth, contract manufacturers providing GMP-grade plasmids are trying to keep up with the increasing demand. The recent epidemic situation has aggravated this problem, because many candidate vaccines are being developed, including DNA-based vaccines and mRNA-based vaccines, in which plasmid DNA is needed as the starting material of mRNA transcription in vitro. The continuous growth of downstream demand will promote the development of GMP Plasmid DNA Manufacturing industry.
The manufacturing process of GMP Plasmid DNA Manufacturing is complicated
High-quality plasmid DNA is a key component in cell and gene therapy manufacturing, so it is in great demand. This leads to the need to optimize manufacturing to meet the volume and quality requirements in the manufacture of therapeutic drugs. Because of the large size, shear sensitivity, high viscosity of plasmid DNA (pDNA) and the similarity between pDNA and impurities in the manufacturing process, its manufacturing faces many challenges.
Region Overview:
In 2021, the share of the GMP Plasmid DNA Manufacturing market in North America stood at 45.6%.
Company Overview:
Aldevron is one of the major players operating in the GMP Plasmid DNA Manufacturing market, holding a share of 34.65% in 2021.
Aldevron
Aldevron has grown into a world-class service organization specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe.
Kaneka Eurogentec S.A.
Eurogentec, part of Kaneka Corporation, is an international biotechnology supplier, based in Belgium, who specializes in genomics and proteomics. The company is fully ISO 9001, ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health and approved by the US FDA for the commercial manufacturing of a biologic for the US market.
Segmentation Overview:
As for product types, the Clinical Therapeutics segment held the largest market share in 2021.
Pre-Clinical Therapeutics
Pre-clinical is the stage that begins before clinical practice, during which important feasibility, repeated testing and drug safety data are usually collected in experiments.
Clinical Therapeutics
Clinical refers to direct contact with patients and actual observation of patients.
Marketed Therapeutics
Marketed means product to market stage.
Application Overview:
The market's largest segment by application is the segment Gene Therapy, with a market share of 36.02% in 2021.
Gene Therapy
Gene Therapy focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material.
DNA Vaccines
DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response.
Immunotherapy
Immunotherapy is the treatment of disease by activating or suppressing the immune system.
This report elaborates on the market size, market characteristics, and market growth of the GMP Plasmid DNA Manufacturing industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of GMP Plasmid DNA Manufacturing. The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global GMP Plasmid DNA Manufacturing Market Report Include:
Market Size Estimates: GMP Plasmid DNA Manufacturing market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: GMP Plasmid DNA Manufacturing market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the GMP Plasmid DNA Manufacturing market
Segment Market Analysis: GMP Plasmid DNA Manufacturing market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: GMP Plasmid DNA Manufacturing market situations and prospects in major and top regions and countries
GMP Plasmid DNA Manufacturing Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.GMP Plasmid DNA Manufacturing Industry Chain: GMP Plasmid DNA Manufacturing market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
GMP Plasmid DNA Manufacturing Industry News, Policies by regions
GMP Plasmid DNA Manufacturing Industry Porters Five Forces Analysis
Key players in the global GMP Plasmid DNA Manufacturing market are covered in Chapter 2:
VGXI, Inc
Esco Aster
Biovian
LakePharma
Charles River
VectorBuilder
Thermo Fisher Scientific
GenScript ProBio
Nature Technology Corporation
Catalent Biologics
BioXcellence
PlasmidFactory
Creative Biolabs
WuXi Advanced Therapies
Waisman Biomanufacturing
Kaneka Eurogentec S.A.
Aldevron
In Chapter 6 and Chapter 9, on the basis of types, the GMP Plasmid DNA Manufacturing market from 2018 to 2028 is primarily split into:
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
In Chapter 7 and Chapter 10, on the basis of applications, the GMP Plasmid DNA Manufacturing market from 2018 to 2028 covers:
Gene Therapy
DNA Vaccines
Immunotherapy
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global GMP Plasmid DNA Manufacturing market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the GMP Plasmid DNA Manufacturing industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of GMP Plasmid DNA Manufacturing market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the GMP Plasmid DNA Manufacturing industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on GMP Plasmid DNA Manufacturing market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the GMP Plasmid DNA Manufacturing market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed GMP Plasmid DNA Manufacturing market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
